COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,235 Articles (22,733 medRxiv, 8,502 bioRxiv)

Most recent first Previous |  Page 2031: Articles 20301-20310  | Next

Which policies most effectively reduce SARS-CoV-2 transmission in schools?
Bershteyn, A., Kim, H.-Y., McGillen, J. B., Braithwaite, R. S.
10.1101/2020.11.24.20237305 — Posted: 2020-11-27
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro
Raymonda, M. H., Ciesla, J. H., Monaghan, M., Leach, J., Asantewaa, G., Smorodintsev-Schiller, L. A., Lutz, M. M., Schafer, X. L., Takimoto, T., Dewhurst, S., Munger, J., Harris, I. S.
10.1101/2020.11.25.398859 — Posted: 2020-11-26
Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
Ginez, T., Garaigorta, U., Ramirez, D., Castro, V., Nozal, V., Maestro, I., Garcia-Carceles, J., Campillo, N. E., Martinez, A., Gastaminza, P., Gil, C.
10.1101/2020.11.26.399436 — Posted: 2020-11-26
Triple Combination Nitazoxanide, Ribavirin, and Hydroxychloroquine results in the multiplicative reduction of in vitro SARS-CoV-2 viral replication
Lian, E., McAlister, C., Ramirez, G., Chernoff, D. N., Went, G., Hoopes, J., Perera, R.
10.1101/2020.11.25.399055 — Posted: 2020-11-26
Massively parallel interrogation of protein fragment secretability using SECRiFY reveals features influencing secretory system transit
Boone, M., Ramasamy, P., Zuallaert, J., Bouwmeester, R., Van Moer, B., Maddelein, D., Turan, D., Hulstraert, N., Eeckhout, H., Vandermarliere, E., Martens, L., Degroeve, S., De Neve, W., Vranken, W., Callewaert, N.
10.1101/241349 — Posted: 2020-11-26 Discussion: Onsite
Inactivation of SARS-CoV-2 on surfaces and in solution with Virusend (TX-10), a novel disinfectant
Anderson, E. R., Hughes, G., Patterson, E. I.
10.1101/2020.11.25.394288 — Posted: 2020-11-26
Exploring Risks of Human Challenge Trials for COVID-19
Manheim, D., Wiecek, W., Schmit, V., Morrison, J.
10.1101/2020.11.19.20234658 — Posted: 2020-11-26
High-resolution mapping and characterization of epitopes in COVID-19 patients
Haynes, W. A., Kamath, K., Bozekowski, J., Baum-Jones, E., Campbell, M., Casanovas-Massana, A., Daugherty, P. S., Dela Cruz, C. S., Dhal, A., Farhadian, S. F., Fitzgibbons, L., Fournier, J., Jhatro, M., Jordan, G., Kessler, D., Klein, J., Lucas, C., Luchsinger, L. L., Martinez, B., Muenker, M. C., Pischel, L., Reifert, J., Sawyer, J. R., Waitz, R., Wunder, E. A., Zhang, M., Yale IMPACT Team, , Iwasaki, A., Ko, A. I., Shon, J. C.
10.1101/2020.11.23.20235002 — Posted: 2020-11-26
Diabetes and Mortality Among 1.6 Million Adult Patients Screened for SARS-CoV-2 in Mexico
Woolcott, O. O., Castilla-Bancayan, J. P.
10.1101/2020.11.25.20238345 — Posted: 2020-11-26 Discussion: Onsite
Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: a patient-level meta-analysis
Sheerin, D., Abhimanyu, A., Wang, X., Johnson, W. E., Coussens, A.
10.1101/2020.11.25.20236646 — Posted: 2020-11-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).